Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands

Anouk Jochems, Maartje G. Schouwenburg, Brenda Leeneman, Margreet G. Franken, Alfons J. M. van den Eertwegh, John B. A. G. Haanen, Hans Gelderblom, Carin A. Uyl-de Groot, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Willeke A. M. Blokx, Mathilde C. Cardous-Ubbink, Gerard Groenewegen, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Rutger H. Koornstra, Wim H. Kruit, Marieke W. Louwman, Djura PiersmaRozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michel W. J. M. Wouters, Jacobus J. M. van der Hoeven*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)156-165
Number of pages10
JournalEuropean Journal of Cancer
Volume72
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Quality assurance
  • Metastatic melanoma
  • Checkpoint inhibitors
  • MAP kinase inhibitors
  • Population-based
  • Registry
  • Ipilimumab
  • OPEN-LABEL
  • FOLLOW-UP
  • VEMURAFENIB
  • SURVIVAL
  • INDICATORS
  • IPILIMUMAB
  • MUTATION
  • CANCER
  • SAFETY

Cite this